Literature DB >> 19536845

Sequential evaluation of serum hepcidin in anemic myeloma patients: study of correlations with myeloma treatment, disease variables, and anemia response.

Eirini Katodritou, Tomas Ganz, Evangelos Terpos, Evgenia Verrou, Gordana Olbina, Vassiliki Gastari, Christina Hadjiaggelidou, Maria Varthaliti, Sofia Georgiadou, Mark Westerman, Konstantinos Zervas.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19536845     DOI： 10.1002/ajh.21448

Source DB:  PubMed          Journal:  Am J Hematol        ISSN： 0361-8609            Impact factor:   10.047


× No keyword cloud information.
  8 in total

1.  Erythroblast apoptosis and microenvironmental iron restriction trigger anemia in the VK*MYC model of multiple myeloma.

Authors:  Jessica Bordini; Maria Teresa Sabrina Bertilaccio; Maurilio Ponzoni; Isabella Fermo; Marta Chesi; P Leif Bergsagel; Clara Camaschella; Alessandro Campanella
Journal:  Haematologica       Date:  2015-02-24       Impact factor: 9.941

2.  Time-of-flight mass spectrometry analysis of the ferroportin-hepcidin binding domain complex for accurate mass confirmation of bioactive hepcidin 25.

Authors:  David K Crockett; Mark M Kushnir; John D Phillips; Alan L Rockwood
Journal:  Clin Chim Acta       Date:  2009-12-03       Impact factor: 3.786

3.  Iron increases the susceptibility of multiple myeloma cells to bortezomib.

Authors:  Alessandro Campanella; Paolo Santambrogio; Francesca Fontana; Michela Frenquelli; Simone Cenci; Magda Marcatti; Roberto Sitia; Giovanni Tonon; Clara Camaschella
Journal:  Haematologica       Date:  2012-12-14       Impact factor: 9.941

Review 4.  Iron in multiple myeloma.

Authors:  Kristina VanderWall; Tracy R Daniels-Wells; Manuel Penichet; Alan Lichtenstein
Journal:  Crit Rev Oncog       Date:  2013

5.  Hepcidin and GDF15 in anemia of multiple myeloma.

Authors:  Shuchong Mei; Huaquan Wang; Rong Fu; Wen Qu; Limin Xing; Guojin Wang; Jia Song; Hong Liu; Lijuan Li; Xiaoming Wang; Yuhong Wu; Jin Guan; Erbao Ruan; Zonghong Shao
Journal:  Int J Hematol       Date:  2014-07-23       Impact factor: 2.490

6.  Dilemma: Correlation Between Serum Level of Hepcidin and IL-6 in Anemic Myeloma Patients.

Authors:  Lejla Ibricevic-Balic; Emina Icindic-Nakas; Sabaheta Hasic; Emina Kiseljakovic; Alma Sofo-Hafizovic; Sefkija Balic
Journal:  Med Arch       Date:  2016-12

Review 7.  New Biomarkers of Ferric Management in Multiple Myeloma and Kidney Disease-Associated Anemia.

Authors:  Małgorzata Banaszkiewicz; Jolanta Małyszko; David H Vesole; Karolina Woziwodzka; Artur Jurczyszyn; Marcin Żórawski; Marcin Krzanowski; Jacek Małyszko; Krzysztof Batko; Marek Kuźniewski; Katarzyna Krzanowska
Journal:  J Clin Med       Date:  2019-11-01       Impact factor: 4.241

8.  Serum prohepcidin levels are potential prognostic markers in patients with multiple myeloma.

Authors:  Kouichi Haraguchi; Hirofumi Uto; Nobuhito Ohnou; Masahito Tokunaga; Mayumi Tokunaga; Atae Utsunomiya; Shuichi Hanada; Hirohito Tsubouchi
Journal:  Exp Ther Med       Date:  2012-08-18       Impact factor: 2.447
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.